October 28, 2021

The paper of peptidomimetics is published in ACS Omega

This paper presents the new method to analyze how peptidomimetics scaffold mimic the actual peptide, and PRISM’s scaffold advantage is confirmed.
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)
Read More
September 9, 2021

PRISM BioLab raised 1.3 billion yen in Series C funding

PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today...
Read More
June 16, 2021

Servier and PRISM BioLab enter drug discovery collaboration for a novel target

PRISM BioLab provides PepMetics® (peptide mimetic small molecules) Technology for generating Hit and Lead compounds against...
Read More
November 4, 2020

PRISM Biolab and Merck enter multi-project drug discovery collaboration

PRISM Biolab provides The PRISM Library, proprietary library of peptide mimetic small molecules for screening against...
Read More
June 8, 2020

PRISM Biolab and Boehringer Ingelheim enter multi-project drug discovery collaboration

PRISM Biolab provides The PRISM Library, proprietary library of peptide mimetic small molecules for screening against...
Read More
November 12, 2018

Notice of Our Merger

PRISM Pharma Co.,Ltd. (“Pharma”) and its wholly owned subsidiary, PRISM BioLab Co.,Ltd.(“BioLab”), have merged as of...
Read More
1 2 3